Release Date ![[down]](http://us.i1.yimg.com/us.yimg.com/i/fi/down.gif) |
Contributor |
Author |
Title |
Pages |
Price |
StarMine Author Rating | More Info |
| EPS Accuracy * |
Portfolio Return ** |
| 18-Nov-09 | Caris & Company | Chris Warren | COV-F10 Guidance Raised Despite Additional SG&A Spend | 8 | $25 | | | View Abstract |
| 12-Nov-09 | Caris & Company | Chris Warren | MMSI-New Guidewire Offers Blueprint for Transformation | 8 | $25 | | | View Abstract |
| 2-Nov-09 | Caris & Company | Chris Warren | MedTech - Smaller Catheters Can Eliminate Vasc. Closure Devices | 4 | $10 | | | View Abstract |
| 29-Oct-09 | Caris & Company | Chris Warren | SPNC-8% 3Q Revenue Growth Driven Internationally, Old: $6, New: $7 | 10 | $25 | | | View Abstract |
| 28-Oct-09 | Caris & Company | Chris Warren | Caris Company Update/EVVV-3Q09 Upside As Neuro Shines | 9 | $25 | | | View Abstract |
| 26-Oct-09 | Caris & Company | Chris Warren | MedTech - Exploring the Case for Reprocessing Pacemakers | 4 | $10 | | | View Abstract |
| 22-Oct-09 | Caris & Company | Chris Warren | BCR - 3Q Results Show Internal Progress | 8 | $25 | | | View Abstract |
| 21-Oct-09 | Caris & Company | Chris Warren | VASC - 3Q Well Done: 11% Rev. Growth | 8 | $25 | | | View Abstract |
| 21-Oct-09 | Caris & Company | Chris Warren | BSX - Diminishing 2010 Prospects | 8 | $25 | | | View Abstract |
| 26-Mar-09 | Caris & Company | Chris Warren | BCR - Playing Hernia Defense Until New Products Launch | 7 | $30 | | | View Abstract |